| Autor: |
Pandey, Jyoti, Mandha, Mallesh, Khan, Mohd Ruman, Ghara, Abhishek, Nayak, Soumyadip, Chakraborthy, Gunosindhu, Mehta, Farhad F., Kumar, M. R. Pradeep |
| Předmět: |
|
| Zdroj: |
Biochemical & Cellular Archives; Oct2024, Vol. 24 Issue 2, p2761-2770, 10p |
| Abstrakt: |
Multitarget histone deacetylase inhibitors (MT-HDACi) have emerged as a promising therapeutic strategy in cancer treatment, addressing the limitations of traditional single-target therapies. This review explores the role of histone deacetylases in epigenetic regulation and their implications in cancer biology. A particular focus is placed on the BRD4-LIFRJAK1-STAT3 signaling pathway, which has been implicated in promoting drug resistance. The interplay between these molecular targets highlights the complexity of oncogenic signaling and the challenges associated with effective cancer therapy. MTHDACi offer the potential to simultaneously inhibit multiple pathways, thereby disrupting the mechanisms of drug resistance mediated by BRD4 and its downstream effectors. Furthermore, this review emphasizes the importance of understanding resistance mechanisms to enhance the design and development of MT-HDACi. By integrating insights from molecular biology, pharmacology, and translational research, this work advocates for continued exploration of multitargeted approaches as a viable strategy for improving therapeutic outcomes in cancer patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
